Endogenous activation of group-II metabotropic glutamate receptors inhibits the hypothalamic-pituitary-adrenocortical axis

S. Scaccianoce, F. Matrisciano, P. Del Bianco, A. Caricasole, V. Di Giorgi Gerevini, I. Cappuccio, D. Melchiorri, G. Battaglia, F. Nicoletti

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

Systemic injection of the mGlu2/3 receptor antagonist, LY341495 (1 mg/kg, i.p.), increased plasma corticosterone in mice to an extent similar to that induced by the despair test. Treatment with the mGlu2/3 receptor agonist, LY379268 (1 mg/kg, i.p.), or the non-competitive mGlu5 receptor antagonist, MPEP (5 mg/kg, i.p.), failed to induce significant changes in corticosterone levels. Searching for a site of action of LY341495, we examined the expression of mGlu receptor subtypes in the various anatomical regions of the mouse hypothalamic-pituitary-adrenal (HPA) axis. Only mGlu5 and -7 receptor mRNAs were detected in the adrenal gland by RT-PCR, whereas mGlu -1, -3, -4, -5, -7 and -8 receptor mRNAs were detected in the anterior pituitary. All transcripts (with the exception of mGlu5 and mGlu6 receptor mRNAs) were detected in the hypothalamus. However, Western blot analysis showed the presence of mGlu2/3 receptor proteins only in the hypothalamus and not in the anterior pituitary. This was consistent with functional data showing that LY341495 (0.1 and 1 μM) failed to affect ACTH secretion from isolated mouse anterior pituitaries. Moving from these observations, we examined whether LY341495 could activate the HPA axis by inhibiting mGlu2/3 receptors at hypothalamic level. We measured the release of corticotropin releasing hormone (CRH) in isolated mouse hypothalami incubated in the presence of subtype-selective mGlu receptor agonists or antagonists. Among all the drugs we have tested, only LY341495 was able to increase CRH secretion. With high concentrations of LY341495 (1 μM) this increase was similar to that induced by 50 mM K+. The action of LY341495 was prevented by the combined application of the mGlu2/3 receptor agonist, LY379268. We conclude that group-II mGlu receptors tonically regulate the HPA axis by controlling CRH secretion at hypothalamic level.

Original languageEnglish
Pages (from-to)555-561
Number of pages7
JournalNeuropharmacology
Volume44
Issue number5
DOIs
Publication statusPublished - Apr 2003

Fingerprint

LY 341495
Metabotropic Glutamate Receptors
LY 379268
Corticotropin-Releasing Hormone
Hypothalamus
Corticosterone
Messenger RNA
Adrenal Glands
Adrenocorticotropic Hormone
Western Blotting
Polymerase Chain Reaction
Injections

Keywords

  • Corticosterone
  • Hypothalamic-pituitary-adrenal axis
  • Metabotropic glutamate receptors
  • Mice

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Drug Discovery
  • Pharmacology

Cite this

Endogenous activation of group-II metabotropic glutamate receptors inhibits the hypothalamic-pituitary-adrenocortical axis. / Scaccianoce, S.; Matrisciano, F.; Del Bianco, P.; Caricasole, A.; Di Giorgi Gerevini, V.; Cappuccio, I.; Melchiorri, D.; Battaglia, G.; Nicoletti, F.

In: Neuropharmacology, Vol. 44, No. 5, 04.2003, p. 555-561.

Research output: Contribution to journalArticle

Scaccianoce, S, Matrisciano, F, Del Bianco, P, Caricasole, A, Di Giorgi Gerevini, V, Cappuccio, I, Melchiorri, D, Battaglia, G & Nicoletti, F 2003, 'Endogenous activation of group-II metabotropic glutamate receptors inhibits the hypothalamic-pituitary-adrenocortical axis', Neuropharmacology, vol. 44, no. 5, pp. 555-561. https://doi.org/10.1016/S0028-3908(03)00027-3
Scaccianoce S, Matrisciano F, Del Bianco P, Caricasole A, Di Giorgi Gerevini V, Cappuccio I et al. Endogenous activation of group-II metabotropic glutamate receptors inhibits the hypothalamic-pituitary-adrenocortical axis. Neuropharmacology. 2003 Apr;44(5):555-561. https://doi.org/10.1016/S0028-3908(03)00027-3
Scaccianoce, S. ; Matrisciano, F. ; Del Bianco, P. ; Caricasole, A. ; Di Giorgi Gerevini, V. ; Cappuccio, I. ; Melchiorri, D. ; Battaglia, G. ; Nicoletti, F. / Endogenous activation of group-II metabotropic glutamate receptors inhibits the hypothalamic-pituitary-adrenocortical axis. In: Neuropharmacology. 2003 ; Vol. 44, No. 5. pp. 555-561.
@article{fd8200f654c34462b2a4c3462cc81b00,
title = "Endogenous activation of group-II metabotropic glutamate receptors inhibits the hypothalamic-pituitary-adrenocortical axis",
abstract = "Systemic injection of the mGlu2/3 receptor antagonist, LY341495 (1 mg/kg, i.p.), increased plasma corticosterone in mice to an extent similar to that induced by the despair test. Treatment with the mGlu2/3 receptor agonist, LY379268 (1 mg/kg, i.p.), or the non-competitive mGlu5 receptor antagonist, MPEP (5 mg/kg, i.p.), failed to induce significant changes in corticosterone levels. Searching for a site of action of LY341495, we examined the expression of mGlu receptor subtypes in the various anatomical regions of the mouse hypothalamic-pituitary-adrenal (HPA) axis. Only mGlu5 and -7 receptor mRNAs were detected in the adrenal gland by RT-PCR, whereas mGlu -1, -3, -4, -5, -7 and -8 receptor mRNAs were detected in the anterior pituitary. All transcripts (with the exception of mGlu5 and mGlu6 receptor mRNAs) were detected in the hypothalamus. However, Western blot analysis showed the presence of mGlu2/3 receptor proteins only in the hypothalamus and not in the anterior pituitary. This was consistent with functional data showing that LY341495 (0.1 and 1 μM) failed to affect ACTH secretion from isolated mouse anterior pituitaries. Moving from these observations, we examined whether LY341495 could activate the HPA axis by inhibiting mGlu2/3 receptors at hypothalamic level. We measured the release of corticotropin releasing hormone (CRH) in isolated mouse hypothalami incubated in the presence of subtype-selective mGlu receptor agonists or antagonists. Among all the drugs we have tested, only LY341495 was able to increase CRH secretion. With high concentrations of LY341495 (1 μM) this increase was similar to that induced by 50 mM K+. The action of LY341495 was prevented by the combined application of the mGlu2/3 receptor agonist, LY379268. We conclude that group-II mGlu receptors tonically regulate the HPA axis by controlling CRH secretion at hypothalamic level.",
keywords = "Corticosterone, Hypothalamic-pituitary-adrenal axis, Metabotropic glutamate receptors, Mice",
author = "S. Scaccianoce and F. Matrisciano and {Del Bianco}, P. and A. Caricasole and {Di Giorgi Gerevini}, V. and I. Cappuccio and D. Melchiorri and G. Battaglia and F. Nicoletti",
year = "2003",
month = "4",
doi = "10.1016/S0028-3908(03)00027-3",
language = "English",
volume = "44",
pages = "555--561",
journal = "Neuropharmacology",
issn = "0028-3908",
publisher = "Elsevier Limited",
number = "5",

}

TY - JOUR

T1 - Endogenous activation of group-II metabotropic glutamate receptors inhibits the hypothalamic-pituitary-adrenocortical axis

AU - Scaccianoce, S.

AU - Matrisciano, F.

AU - Del Bianco, P.

AU - Caricasole, A.

AU - Di Giorgi Gerevini, V.

AU - Cappuccio, I.

AU - Melchiorri, D.

AU - Battaglia, G.

AU - Nicoletti, F.

PY - 2003/4

Y1 - 2003/4

N2 - Systemic injection of the mGlu2/3 receptor antagonist, LY341495 (1 mg/kg, i.p.), increased plasma corticosterone in mice to an extent similar to that induced by the despair test. Treatment with the mGlu2/3 receptor agonist, LY379268 (1 mg/kg, i.p.), or the non-competitive mGlu5 receptor antagonist, MPEP (5 mg/kg, i.p.), failed to induce significant changes in corticosterone levels. Searching for a site of action of LY341495, we examined the expression of mGlu receptor subtypes in the various anatomical regions of the mouse hypothalamic-pituitary-adrenal (HPA) axis. Only mGlu5 and -7 receptor mRNAs were detected in the adrenal gland by RT-PCR, whereas mGlu -1, -3, -4, -5, -7 and -8 receptor mRNAs were detected in the anterior pituitary. All transcripts (with the exception of mGlu5 and mGlu6 receptor mRNAs) were detected in the hypothalamus. However, Western blot analysis showed the presence of mGlu2/3 receptor proteins only in the hypothalamus and not in the anterior pituitary. This was consistent with functional data showing that LY341495 (0.1 and 1 μM) failed to affect ACTH secretion from isolated mouse anterior pituitaries. Moving from these observations, we examined whether LY341495 could activate the HPA axis by inhibiting mGlu2/3 receptors at hypothalamic level. We measured the release of corticotropin releasing hormone (CRH) in isolated mouse hypothalami incubated in the presence of subtype-selective mGlu receptor agonists or antagonists. Among all the drugs we have tested, only LY341495 was able to increase CRH secretion. With high concentrations of LY341495 (1 μM) this increase was similar to that induced by 50 mM K+. The action of LY341495 was prevented by the combined application of the mGlu2/3 receptor agonist, LY379268. We conclude that group-II mGlu receptors tonically regulate the HPA axis by controlling CRH secretion at hypothalamic level.

AB - Systemic injection of the mGlu2/3 receptor antagonist, LY341495 (1 mg/kg, i.p.), increased plasma corticosterone in mice to an extent similar to that induced by the despair test. Treatment with the mGlu2/3 receptor agonist, LY379268 (1 mg/kg, i.p.), or the non-competitive mGlu5 receptor antagonist, MPEP (5 mg/kg, i.p.), failed to induce significant changes in corticosterone levels. Searching for a site of action of LY341495, we examined the expression of mGlu receptor subtypes in the various anatomical regions of the mouse hypothalamic-pituitary-adrenal (HPA) axis. Only mGlu5 and -7 receptor mRNAs were detected in the adrenal gland by RT-PCR, whereas mGlu -1, -3, -4, -5, -7 and -8 receptor mRNAs were detected in the anterior pituitary. All transcripts (with the exception of mGlu5 and mGlu6 receptor mRNAs) were detected in the hypothalamus. However, Western blot analysis showed the presence of mGlu2/3 receptor proteins only in the hypothalamus and not in the anterior pituitary. This was consistent with functional data showing that LY341495 (0.1 and 1 μM) failed to affect ACTH secretion from isolated mouse anterior pituitaries. Moving from these observations, we examined whether LY341495 could activate the HPA axis by inhibiting mGlu2/3 receptors at hypothalamic level. We measured the release of corticotropin releasing hormone (CRH) in isolated mouse hypothalami incubated in the presence of subtype-selective mGlu receptor agonists or antagonists. Among all the drugs we have tested, only LY341495 was able to increase CRH secretion. With high concentrations of LY341495 (1 μM) this increase was similar to that induced by 50 mM K+. The action of LY341495 was prevented by the combined application of the mGlu2/3 receptor agonist, LY379268. We conclude that group-II mGlu receptors tonically regulate the HPA axis by controlling CRH secretion at hypothalamic level.

KW - Corticosterone

KW - Hypothalamic-pituitary-adrenal axis

KW - Metabotropic glutamate receptors

KW - Mice

UR - http://www.scopus.com/inward/record.url?scp=0037382286&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037382286&partnerID=8YFLogxK

U2 - 10.1016/S0028-3908(03)00027-3

DO - 10.1016/S0028-3908(03)00027-3

M3 - Article

C2 - 12668041

AN - SCOPUS:0037382286

VL - 44

SP - 555

EP - 561

JO - Neuropharmacology

JF - Neuropharmacology

SN - 0028-3908

IS - 5

ER -